Anlotinib in Treatment of Recurrent Small Cell Lung Cancer

NCT03732846 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

43

Enrollment

OTHER

Sponsor class

Conditions

Recurrent Small Cell Lung Cancer

Interventions

DRUG: Anlotinib

Sponsor

Peking University Cancer Hospital & Institute